Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients

NMUH Staff Publications

10

<h4><span style="font-size: 10pt;">AIM:<span style="font-weight: normal;"> </span></span><span style="font-size: 10pt;"><span style="font-weight: normal;">To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy.</span></span></h4><h4><span style="font-size: 10pt;">METHODS: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired <em>t</em>-test at the 5% significance level.</span></span></h4><h4><span style="font-size: 10pt;">RESULTS: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (<em>P</em><0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (<em>P</em><0.001).</span></span></h4><h4><span style="font-size: 10pt;">CONCLUSION: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.</span></span></h4>